CTOs on the Move

Tunstall

www.tunstall.com

 
From its founding in 1777 as California`s first city, San José has been a leader driven by its spirit of innovation. Today, San José stands as the largest city in Northern California and the Capital of Silicon Valley—the world`s leading center of technology innovation. San José is the 10th largest in the U.S., and is committed to remaining a top-ranked place to do business, work, live, play and learn. San José is located in Santa Clara County at the southern edge of the San Francisco Bay, about 50 miles south of San Francisco, 390 miles north of Los Angeles. The ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.tunstall.com
  • 1672 Barrington Street Suite 300
    Halifax, NS CAN B3J 2A2
  • Phone: 902.423.2032

Executives

Name Title Contact Details
Gary Steen
Group Chief Technology Officer Profile

Similar Companies

Decatur Vein Clinic

Decatur Vein Clinic is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Entrust Healthcare

Entrust Healthcare is a Columbus, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Five Rivers Medical Center

Five Rivers Medical Center is a Pocahontas, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aircast

Aircast, Inc. is a Summit, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ampio Pharmaceuticals

Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates.  These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending.  Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™.  The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee.  Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema.  Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.